Article
Endocrinology & Metabolism
Wenjie Shi, Xiaofeng Huang, Ye Wang, Xinyu Wan, Jinzhi He, Yinggang Xu, Weiwei Zhang, Rui Chen, Lu Xu, Xiaoming Zha, Jue Wang
Summary: A nomogram was constructed to predict axillary pathological complete response (pCR) in clinically node-positive (cN+) breast cancer patients receiving neoadjuvant systemic therapy (NST), aiming to assist surgeons in making surgical decisions on the axilla.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ji Hee Kim, Vivian Youngjean Park, Hye Jung Shin, Min Jung Kim, Jung Hyun Yoon
Summary: This study found that a higher volume ratio of U1/U2 derived from ultrafast DCE-MRI was independently associated with pathological complete response in triple-negative invasive breast cancer. Other kinetic features were also associated with pathological complete response in hormone receptor-positive cancers.
EUROPEAN RADIOLOGY
(2022)
Article
Oncology
Andre Pfob, Chris Sidey-Gibbons, Geraldine Rauch, Bettina Thomas, Benedikt Schaefgen, Sherko Kuemmel, Toralf Reimer, Markus Hahn, Marc Thill, Jens-Uwe Blohmer, John Hackmann, Wolfram Malter, Inga Bekes, Kay Friedrichs, Sebastian Wojcinski, Sylvie Joos, Stefan Paepke, Tom Degenhardt, Joachim Rom, Achim Rody, Marion van Mackelenbergh, Maggie Banys-Paluchowski, Regina Grosse, Mattea Reinisch, Maria Karsten, Michael Golatta, Joerg Heil
Summary: Neoadjuvant systemic treatment is effective for breast cancer patients, but current nonsurgical methods cannot accurately identify patients without residual cancer. We developed an intelligent vacuum-assisted biopsy approach using machine learning algorithm, which can reliably exclude residual cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Annemiek K. E. van Hemert, Josefien P. P. van Olmen, Liesbeth J. J. Boersma, John H. H. Maduro, Nicola S. S. Russell, Jolien Tol, Ellen G. G. Engelhardt, Emiel J. Th. Rutgers, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke H. H. van Duijnhoven
Summary: The purpose of this study is to show that omitting adjuvant radiotherapy in breast cancer patients with pCR after NST can result in low rates of local recurrence and good quality of life.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Huei-Yi Tsai, Tsung-Yu Tsai, Chia-Hui Wu, Wei-Shiuan Chung, Jo-Ching Wang, Jui-Sheng Hsu, Ming-Feng Hou, Ming-Chung Chou
Summary: This study explored the potential of a machine learning model integrating clinical and CT-based radiomics features to predict the pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) in breast cancer patients. The results showed that integrating clinical data and radiomics features significantly improved model performance, achieving an accuracy of 0.87, compared to clinical (0.69) and radiomics (0.78) models. Furthermore, the use of more high-order textural features with high reproducibility further enhanced the model's performance. In conclusion, the integration of clinical and CT-based radiomics features was found to be helpful in predicting pCR to NST in breast cancer patients.
Article
Oncology
Selena J. An, Emilie D. Duchesneau, Paula D. Strassle, Katherine Reeder-Hayes, Kristalyn K. Gallagher, David W. Ollila, Stephanie M. Downs-Canner, Philip M. Spanheimer
Summary: Women with small HER2+ breast cancers may have excellent prognosis with adjuvant single-agent chemotherapy and HER2-targeted therapy. The role of de-escalated therapy in the neoadjuvant setting, however, remains uncertain.
Article
Oncology
Jennifer L. Baker, Antonio Di Meglio, Arnauld S. Gbenou, Mayssam El Mouhebb, Neil M. Iyengar, Stefan Michiels, Paul Cottu, Florence Lerebours, Charles Coutant, Anne Lesur, Oliver Tredan, Laurence Vanlemmens, Christelle Jouannaud, Iona Hrab, Sibille Everhard, Anne-Laure Martin, Patrick Arveux, Andre Fabrice, Ines Vaz-Luis, Lee W. Jones
Summary: The study aimed to investigate the effect of physical activity on chemotherapy completion and response in breast cancer patients. The results showed that there was no significant association between physical activity levels and chemotherapy completion or response.
BRITISH JOURNAL OF CANCER
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Caroline Malhaire, Fatine Selhane, Marie-Judith Saint-Martin, Vincent Cockenpot, Pia Akl, Enora Laas, Audrey Bellesoeur, Catherine Ala Eddine, Melodie Bereby-Kahane, Julie Manceau, Delphine Sebbag-Sfez, Jean-Yves Pierga, Fabien Reyal, Anne Vincent-Salomon, Herve Brisse, Frederique Frouin
Summary: This study found that there is an association between pretreatment MRI descriptors and breast cancer pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). MRI features such as non-spiculated margins and unifocality can independently predict the response of breast cancer to NAC.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
Hiroko Masuda, Kenichi Harano, Sakiko Miura, Ying Wang, Yuko Hirota, Oi Harada, Mohit Kumar Jolly, Yuki Matsunaga, Bora Lim, Anita L. Wood, Napa Parinyanitikul, Hee Jin Lee, Gyungyub Gong, Jason T. George, Herbert Levine, Jangsoon Lee, Xiaoping Wang, Anthony Lucci, Arvind Rao, Brock L. Schweitzer, O. Rayne Lawrence, Robert S. Seitz, Stephan W. Morris, David R. Hout, Seigo Nakamura, Savitri Krishnamurthy, Naoto T. Ueno
Summary: The study found that TNBC molecular subtype and IM signature frequently change after NST, and the results suggest that EMT is promoted in the changed subtypes.
JCO PRECISION ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Soo-Yeon Kim, Nariya Cho, Yunhee Choi, Su Hyun Lee, Su Min Ha, Eun Sil Kim, Jung Min Chang, Woo Kyung Moon
Summary: A nomogram incorporating MRI and clinical-pathologic variables was developed to predict pathologic complete response after neoadjuvant chemotherapy in breast cancer. The nomogram showed good discrimination and calibration abilities, effectively identifying independent variables associated with pCR.
Article
Oncology
Renee W. Y. Granzier, Abdalla Ibrahim, Sergey P. Primakov, Sanaz Samiei, Thiemo J. A. van Nijnatten, Maaike de Boer, Esther M. Heuts, Frans-Jan Hulsmans, Avishek Chatterjee, Philippe Lambin, Marc B. I. Lobbes, Henry C. Woodruff, Marjolein L. Smidt
Summary: This study investigated the use of pretreatment contrast-enhanced MRI-based radiomics for predicting pathologic complete tumor response to neoadjuvant systemic therapy in breast cancer patients. The radiomics features did not provide additional value compared to clinical models, indicating the need for reproducibility studies to select reproducible features for accurate assessment of radiomics potential.
Article
Oncology
Andre Pfob, Chris Sidey-Gibbons, Han-Byoel Lee, Marios Konstantinos Tasoulis, Vivian Koelbel, Michael Golatta, Gaiane M. Rauch, Benjamin D. Smith, Vicente Valero, Wonshik Han, Fiona MacNeill, Walter Paul Weber, Geraldine Rauch, Henry M. Kuerer, Joerg Heil
Summary: The study developed and tested multivariate algorithms to accurately identify breast cancer patients without residual cancer after neoadjuvant treatment. The neural network showed the best performance with a specificity ranging from 65.2% to 67.2% in both test and external validation datasets.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Obstetrics & Gynecology
Carolin Mueller, Gilda Schmidt, Ingolf Juhasz-Boess, Lisa Jung, Sarah Huwer, Erich-Franz Solomayer, Stephanie Juhasz-Boess
Summary: Factors such as age, genetic mutation, recurrent cancer, discontinuation of chemotherapy, and time intervals did not influence pathologic complete response in breast cancer patients, while patients with high Ki67, high grading, Her2 positive tumors, and those participating in clinical trials had a higher chance of achieving pathologic complete response. Patients with Luminal B tumors had a lower chance of achieving pathologic complete response.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2021)
Article
Oncology
Sara P. Myers, Gillian M. Ahrendt, Joanna S. Lee, Jennifer G. Steiman, Atilla Soran, Ronald R. Johnson, Priscilla F. McAuliffe, Emilia J. Diego
Summary: The study revealed that breast pCR and ypN0 primarily occurred in HER2+ and TNBC subtypes, and factors such as age, tumor subtype, and clinical stage were associated with ypN0. The impact of cN status on ypN0 varied among different tumor subtypes.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
David W. Lim, Brittany D. Greene, Nicole J. Look Hong
Summary: Breast pCR is a strong predictor of axillary pCR in women with HER2-positive and triple-negative breast cancers, but a poor predictor in women with hormone receptor-positive disease.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Anesthesiology
H. S. Tan, J. K. Plichta, A. Kong, C. W. Tan, S. Hwang, R. Sultana, M. C. Wright, A. T. H. Sia, B. L. Sng, A. S. Habib
Summary: Identifying factors associated with persistent pain after breast cancer surgery may facilitate risk stratification and individualised management. In this multicenter study, a predictive model was developed from a sample of Asian and American women. The independent risk factors for persistent pain after surgery were found to be age, diabetes, pre-operative pain score at sites other than the breast, previous mastitis, and perceived stress scale.
Article
Oncology
A. L. Nash, Y. Ren, J. K. Plichta, L. H. Rosenberger, A. M. B. van den Bruele, M. L. DiNome, K. Westbrook, E. Shelley Hwang
Summary: This study aimed to explore the impact of chemotherapy on treatment outcomes in young women who underwent Oncotype DX testing. The results showed that among women aged 40-50, chemotherapy was only significantly beneficial for overall survival in patients with pN1 disease and an RS of 31-50.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
A. L. Nash, Y. Ren, J. K. Plichta, L. H. Rosenberger, A. M. B. van den Bruele, M. L. DiNome, K. Westbrook, E. Shelley Hwang
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jennifer K. Plichta, Samantha M. Thomas, Daniel F. Hayes, Mariana Chavez-MacGregor, Kimberly Allison, Jennifer de los Santos, Amy M. Fowler, Armando E. Giuliano, Priyanka Sharma, Benjamin D. Smith, Elizabeth van Eycken, Stephen B. Edge, Gabriel N. Hortobagyi
Summary: This study developed a staging system for patients with metastatic cancer at the time of initial diagnosis, aimed at improving prognostic estimates. The heterogeneity in outcomes for metastatic breast cancer patients could guide future revisions of staging guidelines for newly diagnosed stage IV disease.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ritika Manik, Oluwadamilola M. M. Fayanju
ANNALS OF SURGICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Ritika Manik, Connor B. Grady, Leisha C. Elmore, Jennifer H. Fieber, Gary M. Freedman, Rachel C. Jankowitz, Julia C. Tchou, Jennifer Q. Zhang, Rebecca A. Hubbard, Oluwadamilola M. Fayanju
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Ritika Manik, Connor B. Grady, Leisha C. Elmore, Jennifer H. Fieber, Gary M. Freedman, Rachel C. Jankowitz, Julia C. Tchou, Jennifer Q. Zhang, Rebecca A. Hubbard, Oluwadamilola M. Fayanju
Summary: This study examined the potential impact of neoadjuvant chemotherapy (NACT) on post-mastectomy radiotherapy (PMRT) recommendations for cT3 breast cancer. The results indicated that the use of PMRT was influenced by the response to NACT and the presence of lymph node involvement, rather than in-breast disease alone.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Letter
Oncology
Tej A. Patel, Bhav Jain, Edward Christopher Dee, Scarlett Lin Gomez, Neha Vapiwala, Fumiko Chino, Oluwadamilola M. Fayanju
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Education, Scientific Disciplines
Yoshiko Iwai, Alice Yunzi L. Yu, Samantha M. Thomas, Carolyn S. Quinsey, Georgia M. Beasley, Ranjan Sudan, Oluwadamilola M. Fayanju
Summary: This study assessed the impact of surgical clerkship curricula on students' likelihood of pursuing a surgical residency. The results indicated that offering more extracurricular surgical clinical opportunities was associated with more students choosing surgical careers. However, the duration of the clerkship, the number of required and subspecialty services, and advanced clinical electives did not have a significant influence on students' career choices.
JOURNAL OF SURGICAL EDUCATION
(2023)
Article
Oncology
Therese B. Bevers, Bethany L. Niell, Jennifer L. Baker, Debbie L. Bennett, Ermelinda Bonaccio, Melissa S. Camp, Sona Chikarmane, Emily F. Conant, Mohammad Eghtedari, Meghan R. Flanagan, Jeffrey Hawley, Mark Helvie, Linda Hodgkiss, Tamarya L. Hoyt, Jennifer Ivanovich, Maxine S. Jochelson, Swati Kulkarni, Rachael B. Lancaster, Caitlin Mauer, Jessica Maxwell, Bhavika K. Patel, Mark Pearlman, Liane Philpotts, Donna Plecha, Jennifer K. Plichta, Shadi Shakeri, Mary Lou Smith, Clarie L. Streibert, Roberta M. Strigel, Lusine Tumyan, Nicole S. Winkler, Dulcy E. Wolverton, Mary Anne Bergman, Rashmi Kumar, Katie Stehman
Summary: The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide a practical framework for healthcare providers to screen and evaluate clinical presentations and breast lesions. The expert panel from various disciplines meets regularly to review emerging data and update the recommendations.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2023)
Meeting Abstract
Oncology
Kendra Modell Parrish, Samantha Thomas, Astrid Botty van den Bruele, Gayle DiLalla, Maggie DiNome, Carolyn Menendez, Laura Rosenberger, E. Shelley Hwang, Jennifer Plichta, Akiko Chiba, Hannah Woriax
ANNALS OF SURGICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Sydney Record, Samantha Thomas, Astrid Botty van den Bruele, Akiko Chiba, Gayle DiLalla, Maggie DiNome, Gretchen Kimmick, Laura Rosenberger, Hannah Woriax, E. Shelley Hwang, Jennifer Plichta
ANNALS OF SURGICAL ONCOLOGY
(2023)
Meeting Abstract
Surgery
Laura Noteware, Yi Ren, Amanda Nash, Jennifer K. Plichta, Laura H. Rosenberger, Astrid Botty Van den Bruele, Eun-Sil (Shelley) Hwang
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
(2023)
Article
Oncology
Huiyue Li, Jennifer K. Plichta, Kan Li, Yizi Jin, Samantha M. Thomas, Fei Ma, Li Tang, Qingyi Wei, You-Wen He, Qichen Chen, Yuanyuan Guo, Yueping Liu, Jian Zhang, Sheng Luo
Summary: In both early-stage HR-positive and TNBC patients, HER2-low status was associated with lower pCR rates. HER2-zero status might be considered an adverse prognostic factor for OS in patients not achieving pCR.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Medicine, General & Internal
Sydney M. Record, Tori Chanenchuk, Kendra M. Parrish, Samantha J. Kaplan, Gretchen Kimmick, Jennifer K. Plichta
Summary: This article systematically reviewed prognostic models developed and/or validated for older patients with breast cancer. These models, mostly based on clinico-pathological factors, were used to predict response to treatment, recurrence, and mortality. While external validation was rare, most of the models presented in this review represent promising tools for clinical application.
MEDICINA-LITHUANIA
(2023)